e-Article
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Document Type
Article
Author
Nash, Peter; Kirkham, Bruce; Okada, Masato; Rahman, Proton; Combe, Benard; Burmester, Gerd-Ruediger; Adams, David H; Kerr, Lisa; Lee, Chin; Shuler, Catherine L; Genovese, Mark; Ahmed, Khalid; Alper, Jeffrey; Barkham, Nichol; Bennett, Ralph E.; García, Francisco Javier Blanco; Alonso, Ricardo Blanco; Blumstein, Howard B.; Brooks, Michael S.; Burmester, Gerd-Rüdiger; Cagnoli, Patricia; Caldron, Paul H.; Cantagrel, Alain; Chen, Der-Yuan; Churchill, Melvin A.; Codding, Christine E.; Combe, Benard; Deane, Peter M.G.; Del Giudice, Jose; Deodhar, Atul A.; Dhar, Rajat K.; Dokoupilova, Eva; Egan, Rita M.; Everding, Andrea; Galíndez, Eva; Genovese, Mark; Goddard, David H.; Gottlieb, Alice; Goupille, Philippe; Griffin, Robert M.; Gupta, Ramesh C.; Hall, Stephen; Hatti, Kalpita; Howell, Mary P.; Huang, Yu-Huei; Jajoo, Ramina; Janssen, Namieta M.; Kiltz, Uta; Kivitz, Alan J.; Klein, Steven J.; Korkosz, Mariusz P.; Kotha, Roshan; Kremer, Joel M.; Lue, Cummins; de la Fuente, José Luis Marenco; Marzo-Ortega, Helena; Masmitja, Jordi Gratacós; Mease, Philip J.; Meroni, Pier Luigi; Mueller, Eric C.; Nandagudi, Anupama C.; Nash, Peter; Fernández-Nebro, Antonio; Neuwelt, Clark M.; Orbai, Ana Maria; Oza, Meera R.; Parks, Deborah L.; Pattanaik, Debendra; Rell-Bakalarska, Maria E.; Rosmarin, David; Roussou, Euthalia; Rychlewska-Hanczewksa, Anna I.; Sikes, David H.; Stack, Michael T.; Sunkureddi, Prashanth; Tahir, Hasan; Thaçi, Diamant; Tsai, Tsen-Fang; Turkiewicz, Anthony M.; Unger, Leonore; Cabello, Raúl Veiga; Wagner, Ulf; Wei, Cheng-Chung; Wells, Alvin F.; Youssef, Peter; Zielinska, Agnieszka
Source
The Lancet; June 2017, Vol. 389 Issue: 10086 p2317-2327, 11p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy and safety of ixekizumab, a monoclonal antibody that selectively targets interleukin-17A, in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor inhibitors.